Isobutane

Isobutane

SCHEMBL2035704

CC(C)C.CC(C)C.CN1Cc2c(Br)cccc2C1=O.N.O=C(O)O.O=C(O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Isobutane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBLB Q13191 1/20 0.41
PIM1 P11309 1/20 0.37
CSNK1A1 P48729 1/20 0.37
CDK5 Q00535 1/20 0.37
ROCK1 Q13464 1/20 0.37
DYRK1A Q13627 1/20 0.37
LRRK2 Q5S007 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
GRM1 Q13255 1/20 0.36
THRB P10828 1/20 0.36
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36
PARP1 P09874 1/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1333882 0.87 PIM1 (0.46) CBLBPIM1CSNK1A1CDK5ROCK1
SCHEMBL6094662 0.75 PIM1 (0.41) CBLBPIM1CSNK1A1CDK5ROCK1
SCHEMBL17517176 0.75 IDH1 (0.46) CBLBPIM1CSNK1A1CDK5ROCK1
SCHEMBL18368359 0.73 DPP4 (0.43) LMNAKMT2ATSHRCYP3A4
SCHEMBL5839859 0.73 POLB (0.50) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL29777577 0.73 POLB (0.50) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL19370098 0.73 CRBN (0.48) THRBPARP1LMNAKMT2AMEN1
SCHEMBL2730891 0.72 KDM4E (0.61) CBLBPIM1CSNK1A1CDK5ROCK1
SCHEMBL10086511 0.72 NPC1 (0.66) CBLBGRM1LMNAKMT2AMEN1
SCHEMBL31184839 0.71 IDH1 (0.39) CBLBGRM1PARP1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS CBLB 4041/4885PIM1 329/4885CSNK1A1 397/4885
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS CBLB 4041/4885PIM1 329/4885CSNK1A1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.